- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06268769
Tacrolimus C:D-ratio gemeten bij niertransplantatiepatiënten die eenmaal daags worden behandeld met geneesmiddelen met verlengde afgifte (TaC:Drop)
Multicenter, open-label, gerandomiseerde, tweearmige, superioriteitsstudie met parallelle groepen om de biologische beschikbaarheid en uitvoerbaarheid te beoordelen van twee eenmaal daagse tacrolimusformuleringen, Envarsus® vergeleken met Advagraf™, toegediend aan ontvangers van niertransplantaten
The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.
The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.
Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.
Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Aachen, Duitsland, 52074
- University Hospital Aachen, Department of General, Visceral and Transplant Surgery
-
Berlin, Duitsland, 10117
- Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
-
Bochum, Duitsland, 44892
- Knappschaft Clinic, University Hospital Bochum, Department of Surgery
-
Dresden, Duitsland, 01307
- University Hospital Dresden, Division of Nephrology
-
Hamburg, Duitsland, 20251
- University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
-
Hanover, Duitsland, 30625
- Hannover Medical School, Department of General, Visceral and Transplant Surgery
-
Jena, Duitsland, 07747
- University Hospital Jena, Internal Medicine III, Nephrology
-
Mainz, Duitsland, 55131
- University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
-
Mannheim, Duitsland, 68167
- University Hospital Mannheim, Medical Clinic V
-
Munich, Duitsland, 81377
- LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
-
Münster, Duitsland, 48149
- University Hospital Münster, Medical Clinic D
-
Regensburg, Duitsland, 93053
- University Hospital Regensburg, Department of Nephrology
-
Würzburg, Duitsland, 97080
- University Hospital Würzburg, Medical Clinic I, Department of Nephrology
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Signed and dated written informed consent
- Adult (≥18 years old) male or female
- Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
- ABO blood type compatible with the donor kidney
- Able to swallow an oral formulation of tacrolimus in tablet or capsule form
Exclusion Criteria:
- Multi-organ transplantation
- Any previous solid organ transplantation (other than a first kidney allograft)
- For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
- Patient and/or donor is positive for active HCV, HBV or HIV infection
- History of any malignancy that could not be curatively treated
- Ongoing abuse of drugs or alcohol
- Signs of advanced liver disease or any signs of liver decompensation
- Ongoing uncontrolled systemic infection
- Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
- Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
- Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
- Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
- Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
- Inability to freely give informed consent (e.g. individuals under legal guardianship)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Envarsus
Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Andere namen:
|
|
Actieve vergelijker: Advagraf
Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Tijdsspanne: 12 weeks after kidney transplantation
|
To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory. |
12 weeks after kidney transplantation
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage patiënten met dalwaarden lager, binnen of hoger dan het streefbereik
Tijdsspanne: 4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
|
|
Gemiddelde tacrolimusdalspiegel en inter-patiëntvariabiliteit (bereik) van tacrolimusdalspiegels
Tijdsspanne: 4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
|
|
Gemiddelde dagelijkse dosis tacrolimus en inter-patiëntvariabiliteit (bereik) van de dagelijkse dosis tacrolimus
Tijdsspanne: 4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
4 dagen, 14 dagen, 28 dagen en 12 weken na niertransplantatie
|
|
|
Variabiliteit binnen de patiënt van de C/D-ratio en de dagelijkse dosis
Tijdsspanne: Gemeten over de tijdstippen: dag 4, dag 14, dag 28 en week 12
|
Gemeten over de tijdstippen: dag 4, dag 14, dag 28 en week 12
|
|
|
Incidentie van biopsieën vanwege de oorzaak
Tijdsspanne: 12 weken na niertransplantatie
|
12 weken na niertransplantatie
|
|
|
Incidentie van acute afstotingsepisoden die behandeling vereisen
Tijdsspanne: 12 weken na niertransplantatie
|
12 weken na niertransplantatie
|
|
|
Incidentie van steroïde-resistente episoden van door biopsie bewezen acute afstoting
Tijdsspanne: 12 weken en 1 jaar na niertransplantatie
|
12 weken en 1 jaar na niertransplantatie
|
|
|
Incidentie van CMV- en BKV-infectie (inclusief orgaanmanifestatie, indien relevant)
Tijdsspanne: 12 weken en 1 jaar na niertransplantatie
|
12 weken en 1 jaar na niertransplantatie
|
|
|
Incidentie, type, ernst en ernst van bijwerkingen (AR's)
Tijdsspanne: 12 weken en 3 jaar na niertransplantatie
|
12 weken en 3 jaar na niertransplantatie
|
|
|
Bloeddruk
Tijdsspanne: 12 weken en 1, 2, 3 jaar na niertransplantatie
|
12 weken en 1, 2, 3 jaar na niertransplantatie
|
|
|
Incidentie van gastro-intestinale stoornissen die diagnostisch onderzoek vereisen
Tijdsspanne: 12 weken en 3 jaar na niertransplantatie
|
12 weken en 3 jaar na niertransplantatie
|
|
|
Herhaling van primaire nierziekte
Tijdsspanne: 12 weken en 3 jaar na niertransplantatie
|
12 weken en 3 jaar na niertransplantatie
|
|
|
Incidentie van de novo DSA
Tijdsspanne: Gedetecteerd binnen het eerste jaar na niertransplantatie
|
Gedetecteerd binnen het eerste jaar na niertransplantatie
|
|
|
Doses en duur van de behandeling met glucocorticosteroïden
Tijdsspanne: 12 weken en 1, 2, 3 jaar na niertransplantatie
|
12 weken en 1, 2, 3 jaar na niertransplantatie
|
|
|
Incidentie en tijd om stopzetting van de behandeling te onderzoeken
Tijdsspanne: 3 jaar na niertransplantatie
|
3 jaar na niertransplantatie
|
|
|
Incidentie, tijd tot en reden voor het terugtrekken van de patiënt uit het onderzoek
Tijdsspanne: 3 jaar na niertransplantatie
|
3 jaar na niertransplantatie
|
|
|
Time to reach the first trough level in target range
Tijdsspanne: Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading |
Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
|
Tacrolimus concentration/dose (C/D) ratio
Tijdsspanne: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site. |
4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
|
Treatment failure rate
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause) |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Time to treatment failure after transplantation
Tijdsspanne: Measured until 3 years after kidney transplantation
|
Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause) |
Measured until 3 years after kidney transplantation
|
|
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition. |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of graft failure
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Mortality rate
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Mortality rate measures death from any cause |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Graft function measured by eGFR (estimated glomerular filtration rate)
Tijdsspanne: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
eGFR calculated according to the CKD-EPI formula |
4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of delayed graft function
Tijdsspanne: Measurable within the first 2 weeks after kidney transplantation
|
Delayed graft function is defined as the need for more than one episode of dialysis after transplantation |
Measurable within the first 2 weeks after kidney transplantation
|
|
Incidence rate of primary non-function of the renal allograft
Tijdsspanne: Measurable within the first 12 weeks after kidney transplantation
|
Primary non-function is defined as the necessity for ongoing chronic dialysis |
Measurable within the first 12 weeks after kidney transplantation
|
|
Incidence of hepatotoxicity
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence of de novo tremor
Tijdsspanne: 12 weeks and 3 years after kidney transplantation
|
Incidence and severity of tremor based on medical assessment by the investigator |
12 weeks and 3 years after kidney transplantation
|
|
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Tijdsspanne: 12 weeks and 3 years after kidney transplantation
|
The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients. |
12 weeks and 3 years after kidney transplantation
|
|
Dose of mycophenolate
Tijdsspanne: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Including both mycophenolate mofetil and mycophenolic acid |
12 weeks and 1, 2, 3 years after kidney transplantation
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Bernhard Banas, MD, University Hospital Regensburg
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TaC:Drop
- 2023-503531-18-00 (Andere identificatie: EUCT Number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .